Strong sales performance and double-digit EPS growth mark achievement of profitability milestone in 2022
Paris, February 3, 2023
Q4 2022 revenue growth of 2.6% in CER and Business EPS(1) 17.4% growth in CER
- Specialty Care grew 18.1%, driven by Dupixent® (€2,402 million, +42.1%) and new product launches
- Vaccine sales (-16.3%) reflect the phases of influenza and PPH sales (Q3 influenza sales: up 32.4%) as well as the ramp-up of unconsolidated Vaxelis® sale
- General Medicines core assets increased by 8.0% while GBU sales were lower (-3.7%) mainly due to Lantus® and spin-off from EUROAPI
- CHC sales increased 6.6%, driven by double-digit growth in the Digestive Wellness, Cough & Cold and Allergy categories
Full year 2022 delivered 7.0% revenue growth and 17.1% EPS growth at CER
- Sales rose to 42,997 million euros, driven by Dupixent® (€8,293m, +43.8%), additional €3bn sales growth, vaccines up 6.3% in line with medium-term growth target and implementation of CHC strategy (+8.6%)
- Mid-term BOI margin target of 30% and cost savings target of €2.5 billion achieved
- Business EPS(1) from €8.26, up 25.9% on a reported basis and 17.1% at CER
- IFRS EPS of €5.37 (plus 8.0%)
- February 2 board meeting proposes annual dividend of €3.56, up 6.9%
Progress on Corporate Social Responsibility strategy in Q4
- Positive phase 2/3 results of acoziborole with the potential to further transform the treatment of sleeping sickness
- Accelerating our goal of net-zero emissions by 5 years, now aiming for 2045
Key R&D milestones and regulatory achievements in Q4
- Double® approved in Europe for prurigo nodularis and positive CHMP opinion for eosinophilic esophagitis
- Beyfortus®(Nirsevimab), approved in Europe for the prevention of RSV disease in all infants
- VidPrevtyn® Beta approved in Europe as a booster vaccine to prevent COVID-19 in adults
- enjaymo® approved in Europe for adult patients with cold agglutinin disease (CAD)
EPS forecast for the full year 2023
- Sanofi…
[ad_2]
Source story
